中晚期宫颈癌同步推量调强放疗的临床研究

doi:10.3760/cma.j.issn.1673-422X.2018.09.007

摘要/Abstract

摘要： 目的研究同步推量调强放疗（SMART）及调强放疗治疗中晚期宫颈癌的临床疗效及不良反应。方法选取2011年4月至2017年4月在我院住院治疗的60例中晚期宫颈癌患者，采用分层区组随机化分组方法，分为试验组30例、对照组30例。两组患者体外放疗同时给予腔内后装放疗及同步化疗。试验组给予SMART，对照组给予调强放疗，两组95%计划靶区（PTV）剂量为50.4 Gy/28 F，试验组肿瘤同步推量靶区剂量为64.4 Gy/28 F。比较两组患者疾病进展情况、生存情况及不良反应。结果放疗结束时，试验组完全缓解（CR）23例，部分缓解（PR）4例，病情稳定（SD）2例，疾病进展（PD）1例；对照组CR 22例，PR 3例，SD 3例，PD 2例；两组患者总体有效率比较，试验组稍高于对照组（90.0%∶83.3%），但差异无统计学意义（χ2=0.144，P=0.704）。3个月后复查，试验组CR 28例，PR 1例，PD 1例；对照组CR 22例，PR 2例，SD 3例，PD 3例；两组患者总体有效率比较，试验组稍高于对照组（96.7%∶80.0%），但差异无统计学意义（χ2=2.588，P=0.108）。试验组、对照组患者的中位生存时间分别为43个月、38个月，差异有统计学意义（χ2=7.087，P=0.008），其中两组患者1年生存率分别为96.6％、85.7%，3年生存率分别为86.2%、60.7%。在放疗不良反应方面，两组患者消化道反应（66.7%∶63.3%， χ2=0.073，P=0.787）、泌尿系统反应（33.3%∶30.0%， χ2=0.077，P=0.781）及骨髓抑制发生率（83.3%∶86.7%， χ2=0.000，P=1.000）比较，差异均无统计学意义。结论中晚期宫颈癌患者SMART疗效优于调强放疗，不良反应可耐受，值得临床推广。

关键词: 宫颈肿瘤, 放射疗法, 调强适形, 同步推量调强放疗, 不良反应

Abstract: ObjectiveTo study the clinical efficiency and adverse reactions of simultaneous modulated accelerated radiotherapy (SMART) and intensitymodulated radiation therapy (IMRT) in advanced cervical cancer. MethodsSixty patients with advanced cervical cancer were collected from April 2011 to April 2017 in our hospital. The 60 patients were randomly divided into experimental group (30 cases) and control group (30 cases) by using stratified randomization method. The two groups were given intracavitary irradiation and concurrent chemotherapy. The patients in experimental group were treated with SMART and the patients in control group were treated with IMRT. 95% planned target volume was 50.4 Gy/28 F in the two groups and the dose for IMRT with simultaneous integrated boost was 64.4 Gy/28 F to the planning target volume. Disease progression, survival time and adverse reactions of the two groups were compared. ResultsAt the end of radiotherapy, the experimental group had 23 patients with complete response (CR), 4 patients with partial response (PR), 2 patients with unaltered stable disease (SD), 1 patient with progressive disease (PD), and the control group had 22 patients with CR, 3 patients with PR, 3 patients with SD, 2 patients with PD. The overall efficiency of the experimental group was slightly higher than that of the control group (90.0% vs. 83.3%), but the difference was not statistically significant (χ2=0.144, P=0.704). After 3 months of radiotherapy, the experimental group had 28 patients with CR, 1 patient with PR, 1 patient with PD, and the control group had 22 patients with CR, 2 patients with PR, 3 patients with SD, 3 patients with PD. The overall efficiency of the experimental group (96.7%) was higher than that of the control group (96.7% vs. 80.0%), but the difference was not statistically significant (χ2=2.588, P=0.108). The median overall survival time of the experimental group and control group were 43 months and 38 months, and the difference was statistically significant (χ2=7.087, P=0.008). The 1year survival rates of the two groups were 96.6% and 85.7%, and the 3year survival rates were 86.2% and 60.7%, respectively. There were no significant differences in the incidences of gastrointestinal reaction (66.7% vs. 63.3%, χ2=0.073, P=0.787), urinary system reaction (33.3% vs. 30.0%, χ2=0.077, P=0.781) and bone marrow suppression (83.3% vs. 86.7%, χ2=0.000, P=1.000) between the two groups. ConclusionThe efficiency of advanced cervical cancer patient treated with SMART is better than IMRT, and the adverse reactions are tolerable, which is worthy of clinical promotion.

Key words: Uterine cervical neoplasms, Radiotherapy, intensitymodulated;, Simultaneous modulated accelerated radiotherapy, Adverse reaction

杨春华,王侠,章龙珍,陈洁,唐天友,刘桂红. 中晚期宫颈癌同步推量调强放疗的临床研究[J]. 国际肿瘤学杂志, 2018, 45(8): 544-547.

Yang Chunhua, Wang Xia, Zhang Longzhen, Chen Jie, Tang Tianyou, Liu Guihong. Clinical study on simultaneous modulated accelerated radiotherapy for advanced cervical cancer[J]. Journal of International Oncology, 2018, 45(8): 544-547.

参考文献

1］俞青青, 唐荣军, 楼军, 等. 同步热放化疗治疗在中晚期宫颈癌的应用价值［J］. 中国妇幼健康研究, 2015, 26(4): 794796. DOI: 10.3969/j.issn.16735293.2015.04.047. ［2］ Zhang G, Fu C, Zhang Y, et al. Extendedfield intensitymodulated radiotherapy and concurrent cisplatinbased chemotherapy for postoperative cervical cancer with connnon iliac or paraaortic lymph node metastases: a retrospective review in a single institution［J］. Int J Gynecol Cancer, 2012, 22(7): 12201225. DOI: 10.1097/ IGC.0b013e3182643b7c. ［3］ Vandecasteele K, Makar A, Van den Broecke R, et al. Intensitymodulated arc therapy with cisplatin as neoadjuvant treatment for primary irresectable cervical cancer. Toxicity, tumor response and outcome［J］. Strahlenhter Onkol, 2012, 188(7): 576581. DOI: 10.1007/s0006601200970. ［4］ Li XL, Chen ZY, Cui YC, et al. Simultaneous modulated accelerated radiotherapy in cervical cancer with retroperitoneal lymph node metastasis after radical hysterectomy and pelvic lymphadenectomy［J］. Int J Gynecol Cancer, 2015, 5(5): 903909. DOI: 10.1097/IGC.0000000000000426. ［5］ Goodman KA, Regine WF, Dawson LA, et al. Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer［J］. Int J Radiat Oncol Biol Phys, 2012, 83(3): 901908. DOI: 10.1016/j.ijrobp.2012.01.022. ［6］ Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66(2): 115132. DOI: 10.3322/caac.21338. ［7］赵宗兴. 局部晚期宫颈癌同步推量调强放疗与常规调强效放疗的计量学比较急早期临床观察［D］. 长春: 吉林大学, 2015．［8］叶玲. 中晚期宫颈癌调强放疗联合同步化疗与常规放疗联合同步化疗临床疗效及不良反应对比观察［J］. 临床和实验医学杂志, 2016, 15(1): 5154. DOI: 10.3969/j.issn.16714695.2016.01.018. ［9］ Tang JM, Ma XM, Hou YL, et al. Analysis of simultaneous modulated accelerated radiotherapy (SMART) for nasopharyngeal carcinomas［J］. J Radiat Res, 2014, 55(4): 794802. DOI: 10.1093/ jrr/ rru012. ［10］ Ippolito E, Cellini N, Diqesù C, et al. Postoperative intensitymodulated radiotherapy with simultaneous integrated boost in prostate cancer: a doseescalation trial［J］. Urol Oncol, 2013, 31(1): 8792. DOI: 10.1016/ j.urolonc.2010.10.005. ［11］ Boyle J, Craciunescu O, Steffey B, et al. Methods, safety, and early clinical outcomes of dose escalation using simultaneous integrated and sequential boosts in patients with locally advanced gynecologic malignancies［J］. Gynecol Oncol, 2014, 135(2): 239243. DOI: 10.1016/ j.Ygyno.2014.08.037.

[1]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[2]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[3]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[4]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[5]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[6]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[7]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[8]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[9]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[10]	邓隽军, 赵大勇, 李淼. 免疫检查点抑制剂在非小细胞肺癌治疗中的不良反应及危险因素[J]. 国际肿瘤学杂志, 2023, 50(9): 564-568.
[11]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[12]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[13]	吕璐, 孙鹏飞. 肠道菌群与宫颈癌[J]. 国际肿瘤学杂志, 2023, 50(6): 373-376.
[14]	许萌, 姜伟, 朱海涛, 曹雄锋. 癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230.
[15]	石小琪, 汪红艳. 肠道菌群与放射性肠炎的相互作用及研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 244-247.